Microcap Ledger Surrozen, Inc./DE $SRZN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 11,753,558 [10-Q 2026-08-06]
What the company doesAI summary of filing
Surrozen is a pre-revenue biotechnology company developing antibody-based therapeutics that modulate the Wnt signaling pathway for ophthalmic diseases. The company's lead product candidates, SZN-8141 and SZN-8143, combine Wnt pathway activation with inhibition of VEGF and/or IL-6 for treatment of diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema; SZN-8141 is anticipated to enter clinical trials in the second half of 2026. Surrozen generates revenue through milestone payments and royalties from a collaboration agreement with Boehringer Ingelheim for development of SZN-413, a Fzd4-targeted antibody, which generated $15 million in milestone payments as of the filing date. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $10.00M | −$77.33M | −$19.91M | $102.04M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $3.48M | −$242.03M | −$30.24M | $89.25M | [10-K 2026-03-23] |
| FY ended Dec 2024 | $10.65M | −$63.56M | −$17.63M | $34.56M | [10-K 2026-03-23] |
- Quarterly cash burn
- −$9.96M
- Cash runway Estimate
- ~30.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 3,249,798 | [10-Q 2024-11-06] |
| 2025-03-25 | 3,281,169 | [10-K 2025-03-31] |
| 2025-05-07 | 8,562,584 | [10-Q 2025-05-09] |
| 2025-08-04 | 8,570,355 | [10-Q 2025-08-08] |
| 2025-11-05 | 8,571,421 | [10-Q 2025-11-07] |
| 2026-03-19 | 11,486,707 | [10-K 2026-03-23] |
| 2026-05-04 | 11,610,371 | [10-Q 2026-05-06] |
| 2026-08-04 | 11,753,558 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-03-23; declared effective 2026-03-30 [S-3 2026-03-23]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-22 | Tcg Crossover Gp Ii, Llc | sell | 162,500 | $21.25 | [4 2026-07-24] |
| 2026-07-22 | Tcg Crossover Gp Ii, Llc | sell | 162,500 | $21.25 | [4 2026-07-24] |
| 2026-06-15 | Maleki Andrew Pedrum | grant | 607 | $19.01 | [4 2026-06-16] |
| 2026-06-15 | Li Yang | grant | 1,666 | $8.11 | [4 2026-06-16] |
| 2026-06-15 | Williams Charles O | grant | 1,666 | $8.11 | [4 2026-06-16] |
| 2026-06-15 | Parker Craig C | grant | 1,622 | $8.11 | [4 2026-06-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-10-02 | 8-K | Other events |
| 2026-10-01 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-24 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-18 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $SRZN
Email me when Surrozen, Inc./DE files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.